Clinical trial

Linagliptin Inpatient Trial

NCT02004366

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-01-01

PhasePHASE4

Study timeline

Study start (actual)2014-01-01Date precision: month

Registry last updated2019-02-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Interventions

LinagliptinDRUG · verified · RxNorm: linagliptin

Basal BolusDRUG

LinagliptinDRUG · verified · RxNorm: linagliptin

Linagliptin + 50% Glargine dose on dischargeDRUG

Linagliptin + 80% GlargineDRUG

Sponsors & collaborators

Emory Universitylead sponsor

Boston Medical Centercollaborator

Rush Universitycollaborator

University of Denvercollaborator

Mapped research locations

AtlantaGeorgia, United States2 BostonMassachusetts, United States1 ChicagoIllinois, United States1 DenverColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02004366 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.